Skip to main content
SpringerLink
Log in

Systemic Therapy: Current Strategies and New Directions

  • Chapter
  • First Online:
Biliary Tract and Gallbladder Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 1774 Accesses

Abstract

A majority of patients diagnosed with malignancy of the intrahepatic bile ducts, (cholangiocarcinoma) or the extrahepatic bile ducts, either present initially with extensive unresectable disease, or will either develop recurrent disease after surgical resection. These patients will need systemic treatment with chemotherapy to palliate symptoms and prolong survival. Many challenges are faced with the development of effective chemotherapy regimens for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ishizawa T, Mise Y, Aoki T et al (2010) Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC: the Eastern perspective. J Hepatobiliary Pancreat Sci 17:389–393

    Article  PubMed  Google Scholar 

  2. LaFemina J, Jarnagin WR (2012) Surgical management of proximal bile duct cancers. Langenbecks Arch Surg 397:869–879

    Article  PubMed  Google Scholar 

  3. Kawakubo K, Isayama H, Mizuno S et al (2013) One-step, simultaneous triple endoscopic nasobiliary drainage for hilar biliary stricture. Dig Endosc 25:76–79

    Article  PubMed  Google Scholar 

  4. Valle JW (2010) Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol 21(Suppl 7):vii345–vii348

    Google Scholar 

  5. de Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29:3140–3145

    Article  PubMed  Google Scholar 

  6. Gerhardt T, Rings D, Hoblinger A et al (2010) Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol 48:28–32

    Article  PubMed  CAS  Google Scholar 

  7. Nathan H, Aloia TA, Vauthey JN et al (2009) A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16:14–22

    Article  PubMed  Google Scholar 

  8. Blechacz B, Komuta M, Roskams T et al (2011) Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8:512–522

    Article  PubMed Central  PubMed  Google Scholar 

  9. Aishima S, Fujita N, Mano Y et al (2009) Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol 35:590–598

    Google Scholar 

  10. Chung YE, Kim MJ, Park YN et al (2009) Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 29:683–700

    Article  PubMed  Google Scholar 

  11. Inui K, Yoshino J, Miyoshi H (2009) Differential diagnosis and treatment of biliary strictures. Clin Gastroenterol Hepatol 7:S79–S83

    Article  PubMed  Google Scholar 

  12. Motosugi U, Ichikawa T, Nakajima H et al (2009) Cholangiolocellular carcinoma of the liver: imaging findings. J Comput Assist Tomogr 33:682–688

    Article  PubMed  Google Scholar 

  13. Kim SH, Lee WJ, Lim HK et al (2007) Sclerosing hepatic carcinoma: helical CT features. Abdom Imaging 32:725–729

    Article  PubMed  Google Scholar 

  14. Gu XJ, Wang BF, Liu R (2012) Application of (1)(8)F-fluorodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of hilar cholangiocarcinoma. Zhonghua Yi Xue Za Zhi 92:1409–1412

    PubMed  Google Scholar 

  15. Alvaro D, Bragazzi MC, Benedetti A et al (2011) Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease. Dig Liver Dis 43:60–65

    Article  PubMed  Google Scholar 

  16. Lee SW, Kim HJ, Park JH et al (2010) Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 45:560–566

    Article  PubMed  Google Scholar 

  17. Wehbe H, Henson R, Meng F et al (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66:10517–10524

    Article  PubMed  CAS  Google Scholar 

  18. Fava G, Alpini G, Rychlicki C et al (2008) Leptin enhances cholangiocarcinoma cell growth. Cancer Res 68:6752–6761

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Marin JJ, Romero MR, Briz O (2010) Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem 17:709–740

    Article  PubMed  CAS  Google Scholar 

  20. Namwat N, Amimanan P, Loilome W et al (2008) Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy 54:343–351

    Article  PubMed  CAS  Google Scholar 

  21. Kongpetch S, Kukongviriyapan V, Prawan A et al (2012) Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS ONE 7:e34994

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  22. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  23. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

    Article  PubMed  CAS  Google Scholar 

  24. Lin MH, Chen JS, Chen HH et al (2003) A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49:154–158

    Article  PubMed  CAS  Google Scholar 

  25. Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103:111–118

    Article  PubMed  CAS  Google Scholar 

  26. Sasaki T, Isayama H, Nakai Y et al (2012) Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30:708–713

    Article  PubMed  CAS  Google Scholar 

  27. Thongprasert S, Napapan S, Charoentum C et al (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279–281

    Article  PubMed  CAS  Google Scholar 

  28. Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332–2338

    Article  PubMed  CAS  Google Scholar 

  29. Jang JS, Lim HY, Hwang IG et al (2010) Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 65:641–647

    Article  PubMed  CAS  Google Scholar 

  30. Gruenberger B, Schueller J, Heubrandtner U et al (2010) Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 11:1142–1148

    Article  PubMed  CAS  Google Scholar 

  31. Nehls O, Oettle H, Hartmann JT et al (2008) Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98:309–315

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  32. Patt YZ, Hassan MM, Aguayo A et al (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101:578–586

    Article  PubMed  CAS  Google Scholar 

  33. Feisthammel J, Schoppmeyer K, Mossner J et al (2007) Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol 30:319–324

    Article  PubMed  CAS  Google Scholar 

  34. Furuse J, Kasuga A, Takasu A et al (2012) Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci 19:337–341

    Article  PubMed  Google Scholar 

  35. Eckmann KR, Patel DK, Landgraf A et al (2011) Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res 4:155–160

    PubMed Central  PubMed  Google Scholar 

  36. Lubner SJ, Mahoney MR, Kolesar JL et al (2010) Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28:3491–3497

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Bengala C, Bertolini F, Malavasi N et al (2010) Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102:68–72

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  38. El-Khoueiry AB, Rankin CJ, Ben-Josef E et al (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30:1646–1651

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  39. Ramanathan RK, Belani CP, Singh DA et al (2009) A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64:777–783

    Article  PubMed  CAS  Google Scholar 

  40. Bekaii-Saab T, Phelps MA, Li X et al (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357–2363

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  41. Philip PA, Mahoney MR, Allmer C et al (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069–3074

    Article  PubMed  CAS  Google Scholar 

  42. Jensen LH, Lindebjerg J, Ploen J et al (2012) Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 23:2341–2346

    Article  PubMed  CAS  Google Scholar 

  43. Lee J, Park SH, Chang HM et al (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13:181–188

    Article  PubMed  CAS  Google Scholar 

  44. Yi JH, Thongprasert S, Lee J et al (2012) A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 48:196–201

    Article  PubMed  CAS  Google Scholar 

  45. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11:48–54

    Article  PubMed  CAS  Google Scholar 

  46. Utispan K, Sonongbua J, Thuwajit P et al (2012) Periostin activates integrin alpha5beta1 through a PI3 K/AKTdependent pathway in invasion of cholangiocarcinoma. Int J Oncol 41:1110–1118

    PubMed  CAS  Google Scholar 

  47. Mertens JC, Fingas CD, Christensen JD et al (2013) Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res 73:897–907

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  48. Fingas CD, Mertens JC, Razumilava N et al (2012) Targeting PDGFR-beta in cholangiocarcinoma. Liver Int 32:400–409

    PubMed Central  PubMed  CAS  Google Scholar 

  49. Sia D, Hoshida Y, Villanueva A et al (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829–840

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Andersen JB, Thorgeirsson SS (2012) Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 28:266–272

    Article  PubMed  CAS  Google Scholar 

  51. Andersen JB, Spee B, Blechacz BR et al (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142:1021–1031 e15

    Google Scholar 

  52. Yoshikawa D, Ojima H, Iwasaki M et al (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98:418–425

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  53. Yoshikawa D, Ojima H, Kokubu A et al (2009) Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 100:1257–1266

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  54. Boonjaraspinyo S, Boonmars T, Wu Z et al (2012) Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 33:1785–1802

    Article  PubMed  CAS  Google Scholar 

  55. Fingas CD, Bronk SF, Werneburg NW et al (2011) Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 54:2076–2088

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  56. Yoon JH, Werneburg NW, Higuchi H et al (2002) Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 62:6500–6505

    PubMed  CAS  Google Scholar 

  57. Jan YY, Yeh TS, Yeh JN et al (2004) Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 240:89–94

    Article  PubMed Central  PubMed  Google Scholar 

  58. Terada T, Ashida K, Endo K et al (1998) c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 33:325–331

    Article  PubMed  CAS  Google Scholar 

  59. Lai GH, Zhang Z, Shen XN et al (2005) erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129:2047–2057

    Article  PubMed  CAS  Google Scholar 

  60. Kiguchi K, Carbajal S, Chan K et al (2001) Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61:6971–6976

    PubMed  CAS  Google Scholar 

  61. Leone F, Cavalloni G, Pignochino Y et al (2006) Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12:1680–1685

    Article  PubMed  CAS  Google Scholar 

  62. Zhang Z, Oyesanya RA, Campbell DJ et al (2010) Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology 52:975–986

    Article  PubMed  CAS  Google Scholar 

  63. Sirica AE, Lai GH, Endo K et al (2002) Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 22:303–313

    Article  PubMed  CAS  Google Scholar 

  64. Sirica AE, Lai GH, Zhang Z (2001) Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 16:363–372

    Article  PubMed  CAS  Google Scholar 

  65. Han C, Demetris AJ, Stolz DB et al (2006) Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem 281:24831–24846

    Article  PubMed  CAS  Google Scholar 

  66. Han C, Wu T (2005) Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280:24053–24063

    Article  PubMed  CAS  Google Scholar 

  67. Zhang Z, Lai GH, Sirica AE (2004) Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39:1028–1037

    Article  PubMed  CAS  Google Scholar 

  68. Dobashi A, Imazu H, Tatsumi N et al (2013) Quantitative analysis of VEGF-C mRNA of extrahepatic cholangiocarcinoma with real-time PCR using samples obtained during endoscopic retrograde cholangiopancreatography. Scand J Gastroenterol 48:848–855

    Article  PubMed  CAS  Google Scholar 

  69. Benckert C, Jonas S, Cramer T et al (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083–1092

    PubMed  CAS  Google Scholar 

  70. Sugiyama H, Onuki K, Ishige K et al (2011) Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol 46:779–789

    Article  PubMed  CAS  Google Scholar 

  71. Wiedmann MW, Mossner J (2010) Molecular targeted therapy of biliary tract cancer–results of the first clinical studies. Curr Drug Targets 11:834–850

    Article  PubMed  CAS  Google Scholar 

  72. Meng F, Yamagiwa Y, Taffetani S et al (2005) IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway. Am J Physiol Cell Physiol 289:C971–C981

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  73. Tan FL, Ooi A, Huang D et al (2010) p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer 126:2353–2361

    PubMed  CAS  Google Scholar 

  74. Horiuchi H, Kawamata H, Furihata T et al (2004) A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice. J Exp Clin Cancer Res 23:599–606

    PubMed  CAS  Google Scholar 

  75. Horiuchi H, Kawamata H, Fujimori T et al (2003) A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 23:957–963

    PubMed  CAS  Google Scholar 

  76. Radaeva S, Ferreira-Gonzalez A, Sirica AE (1999) Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29:1453–1462

    Article  PubMed  CAS  Google Scholar 

  77. Terada T, Nakanuma Y, Sirica AE (1998) Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 29:175–180

    Article  PubMed  CAS  Google Scholar 

  78. Socoteanu MP, Mott F, Alpini G et al (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 14:2990–2994

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  79. Ge X, Wang Y, Wang Y et al (2013) NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells. Dig Dis Sci 58:1636–1643

    Article  PubMed  CAS  Google Scholar 

  80. Tannapfel A, Sommerer F, Benicke M et al (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706–712

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  81. El Khatib M, Kalnytska A, Palagani V et al (2013) Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 57:1035–1045

    Article  PubMed  CAS  Google Scholar 

  82. Omenetti A, Diehl AM (2011) Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol 27:268–275

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charleston, SC, USA

    Melanie B. Thomas

Authors
  1. Melanie B. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie B. Thomas .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA

    Joseph M. Herman

  2. Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA

    Timothy M. Pawlik

  3. Department of Radiation Oncology, Oregon Health and Science University, Portland, Oregon, USA

    Charles R. Thomas, Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Thomas, M.B. (2014). Systemic Therapy: Current Strategies and New Directions. In: Herman, J., Pawlik, T., Thomas, Jr., C. (eds) Biliary Tract and Gallbladder Cancer. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40558-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-40558-7_18

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-40557-0

  • Online ISBN: 978-3-642-40558-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation